Publication | Open Access

ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial

Lymphoid NeoplasiaMedicineMalignant Blood DisorderLysa H34Versus BeacoppClinical TrialsPathologyOncologyRadiation OncologyCancer ResearchFinal ResultsHealth Sciences